References
- TepedinoMEHellerWHUsnerDWPhase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitisCurr Med Res Opin20092551159116919323612
- KarpeckiPDepaolisMHunterJABesifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety studyClin Ther200931351452619393842
- HovdingGAcute bacterial conjunctivitisActa Ophthalmol200886151717970823
- SheikhAHurwitzBAntibiotics versus placebo for acute bacterial conjunctivitisCochrane Database Syst Rev200622CD00121116625540
- GrasbonTMino de KasparHKlaussVCoagulase-negative staphylococci in normal and chronically inflamed conjunctivaOphthalmologe19959267938018563427
- AsbellPAColbyKADengSOcular TRUST: nationwide antimicrobial susceptibility patterns in ocular isolatesAm J Ophthalmol2008145695195818374299
- United States Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory CommitteeBriefing Package for Besifloxacin hydrochloride ophthalmic suspension for the treatment of bacterial conjunctivitisBausch and Lomb, Inc http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4397b1-00-Index.htmAccessed July 10, 2009
- CambauEMatratSPanXSTarget specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coliJ Antimicrob Chemother200963344345019147516
- WrightDHBrownGHPetersonMLRotschaferJCApplication of fluoroquinolone pharmacodynamicsJ Antimicrob Chemother200046566968311062185
- HyattJMMcKinnonPSZimmerGSSchentagJJThe importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agentsClin Pharmacokinet19952821431607736689
- ForrestANixDEBallowCHGossTFBirminghamMCSchentagJJPharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrob Agents Chemother1993375107310818517694
- AmbrosePGGraselaDMGraselaTHPassarellJMayerHBPiercePFPharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infectionsAntimicrob Agents Chemother200145102793279711557471
- ScaglioneFMoutonJWMattinaRFraschiniFPharmacodynamics of levofloxacin and ciprofloxacin in a murine pneumonia model: peak concentration/MIC versus area under the curve/MIC ratiosAntimicrob Agents Chemother20034792749275512936969
- BedosJPAzoulay-DupuisEMoinePPharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacyJ Pharmacol Exp Ther1998286129359655838
- WagnerRSAbelsonMBShapiroATorkildsenGEvaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissueArch Ophthalmol200512391282128316157821
- TorkildsenGO’BrienTPConjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteersClin Ther200830112005201419108788
- ArnoldDRGranvilCPWardKWProkschJWQuantitative determination of besifloxacin, a novel fluoroquinolone antimicrobial agent, in human tears by liquid chromatography-tandem mass spectrometryJ Chromatogr B Analyt Technol Biomed Life Sci20088671105110
- AiharaMMiyanagaMMinamiKA comparison of fluoroquinolone penetration into human conjunctival tissueJ Ocul Pharmacol Ther200824658759119049265
- RobertsonSMCurtisMASchlechBAOcular pharmacokinetics of moxifloxacin after topical treatment of animals and humansSurv Ophthalmol200550 Suppl 1S32S4516257309
- BowmanLMSiEPangJArchibaldRFriedlaenderMDevelopment of a topical polymeric mucoadhesive ocular delivery system for azithromycinJ Ocul Pharmacol Ther200925213313919284320
- LaPlanteKLRybakMJTsujiBLodiseTPKaatzGWFluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacinAntimicrob Agents Chemother20075141315132017296740
- WilhelmusKREvaluation and prediction of fluoroquinolone pharmacodynamics in bacterial keratitisJ Ocul Pharmacol Ther200319549349914583139
- ProkschJWGranvilCPSiou-MermetRComstockTLPaternoMRWardKWOcular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humansJ Ocul Pharmacol Ther200925433534419492955
- ProkschJWChappaAKHaasWMorrisTWBesifloxacin, moxifloxacin, and gatifloxacin ocular tissue AUC/MIC ratios for fluoroquinolone-resistant organismsAssociation for Research in Vision and Ophthalmology (ARVO)2009 Abstract D905